<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02400281</url>
  </required_header>
  <id_info>
    <org_study_id>ARO-010</org_study_id>
    <nct_id>NCT02400281</nct_id>
  </id_info>
  <brief_title>Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients</brief_title>
  <official_title>Phase I-II Study of Crenolanib Combined With Standard Salvage Chemotherapy, and Crenolanib Combined With 5-Azacitidine in Acute Myeloid Leukemia Patients With FLT3 Activating Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arog Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arog Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, two-arm, Phase I-II trial, non-randomized. Arm 1: crenolanib with
      standard chemotherapy (Idarubicin/Cytarabine, MEC;Mitoxantrone/Etoposide/Cytarabine,
      FLAG-Ida: Fludarabine/Cytarabine/G-CSF/Idarubicin) Arm 2: crenolanib with 5-azacitidine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For each arm:

      The phase I with dose-limiting toxicity (DLT) determination will use 3+3 design.

      Phase II total of 52 patients (26 per arm) will be treated at established phase I dose.

      Enrollment to be simultaneous to each arm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">July 15, 2020</completion_date>
  <primary_completion_date type="Actual">July 15, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities of crenolanib besylate combination therapy</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate of crenolanib besylate combination therapy</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm 1 crenolanib besylate combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 patients will receive crenolanib besylate, combined with standard chemotherapy (Idarubicin/Cytarabine, MEC;Mitoxantrone/Etoposide/Cytarabine, FLAG-Ida: Fludarabine/Cytarabine/G-CSF/Idarubicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 crenolanib besylate combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2 patients will receive crenolanib besylate and azacytidine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crenolanib besylate</intervention_name>
    <arm_group_label>Arm 1 crenolanib besylate combination</arm_group_label>
    <arm_group_label>Arm 2 crenolanib besylate combination</arm_group_label>
    <other_name>CP-868,596-26</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <arm_group_label>Arm 1 crenolanib besylate combination</arm_group_label>
    <other_name>4-demethoxydaunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>Arm 1 crenolanib besylate combination</arm_group_label>
    <other_name>cytosine arabinoside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacytidine</intervention_name>
    <arm_group_label>Arm 2 crenolanib besylate combination</arm_group_label>
    <other_name>5-azacytidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <arm_group_label>Arm 1 crenolanib besylate combination</arm_group_label>
    <other_name>Novantrone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <arm_group_label>Arm 1 crenolanib besylate combination</arm_group_label>
    <other_name>etoposide phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>Arm 1 crenolanib besylate combination</arm_group_label>
    <other_name>Fludarabine phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <arm_group_label>Arm 1 crenolanib besylate combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed diagnosis of refractory/relapsed AML or high-risk MDS

               -  Arm 1: Subjects must have received at least one prior therapy and a maximum of
                  three prior therapies

               -  Arm 2: Subjects must have received at least one prior therapy and a maximum of
                  three prior therapies. No prior treatment with 5-Azacitidine is allowed in this
                  arm.

          2. FLT3 mutation positive (ITD, TKD or other)

          3. ECOG PS 0-2

          4. Adequate liver and renal function

          5. Negative pregnancy test

          6. Extramedullary leukemia allowed except CNS disease

        Exclusion Criteria:

          -  Arm 1 and 2 Exclusion:

               1. &lt;5% blasts in marrow or blood at time of screening

               2. Active HIV, hepatitis B or C

               3. CNS leukemia

               4. Clinically significant GVHD or organ dysfunction where chemotherapy specified by
                  protocol cannot be given

               5. Patient with AML-M3 (APL)

               6. Pre-existing liver diseases (i.e. cirrhosis, chronic hepatitis B or C,
                  nonalcoholic steatohepatitis, sclerosing cholangitis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Cortes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Crenolanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

